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Abstract 
Background and aims: Esophageal squamous cell carcinoma (ESCC) is one of the most 
lethal cancers due to the high frequency of local metastasis. However, the genomic 
landscape of the metastatic ESCC has not been well-characterized. We aim to identify the 
genetic alterations that underlie metastasis in ESCC. Methods: We performed whole-
exome sequencing (WES) for 42 patients with primary ESCC and 15 with metastatic 
ESCC in lymph nodes. Eleven ESCC cases had triple samples including matched primary 
cancer, metastatic cancer in LN and non-neoplastic mucosa. Results: In metastatic 
ESCC, there is a tendency for a weaker APOBEC-mediated signature. Mutations of four 
genes, namely TP53, KMT2D, ZNF750 and IRF5, were frequently found in the metastatic 
ESCC. Importantly, loss-of-function mutations in ZNF750 recurrently occurred in the 
metastatic ESCC and were strongly associated with lymph node  metastasis in the 
primary tumors, suggesting a  role of ZNF750 as a metastasis suppressor. In addition, 
mutations of epigenetic regulators, including KMT2D, TET2 and KAT2A as well as 
deletion of histone variants on chromosomes 6p22 and 11q23 were detected in over half 
of the metastastic ESCCs. Also, copy number gain of the TERT region was less 
frequently observed in these cases. Conclusions: A number of critical genetic events 
including TP53 putative gain-of-functionmissense mutations, mutations of differentiation 
regulators ZNF750 and IRF5, as well as nucleosome disorganization caused by genetic 
lesions, may play an important role in pathogenesis of metastases in ESCC.   
(249 words) 
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Introduction 
Esophageal cancer  is one of the most aggressive cancers and often presents with local 
invasion or regional lymph node (LN) metastasis at diagnosis1. The prognosis of  patients 
with esophageal cancer is poor with 5-year survival rates <50%, after  curative resection2.  
The cancer incidence exhibits remarkable worldwide geographical differences. In the 
Taihang Mountains of Northern China, the incidence rate is up to 133 per 100,0003, while 
Hong Kong is a moderate risk region4 with an incidence rate in males of 10 per 100,0005. 
In the endemic regions, esophageal squamous cell carcinoma (ESCC) is the most 
common histological  type, accounting for approximately 90% of all cases.  
The primary ESCC tumors have been well-characterized by whole-exome 
sequencing (WES) and/or whole-genome sequencing (WGS) in high-risk (Taihang 
Mountains and Chaoshan District)6, 7 and low-risk (Beijing)8, 9 regions of Mainland 
China, and in Japan10. The recent  landscape paper from The Cancer Genome Atlas 
(TCGA) study included 90 ESCC cases from Asian and European populations11. A 
number of driver mutations were identified. However, the molecular profiles of the 
metastatic ESCC remain unclear and the genetic alterations contributing to metastasis 
have not yet been well-characterized.  
In this study, we present the landscape of ESCC somatic alterations from patients 
of Hong Kong,  characterize the metastatic ESCC in LNs by WES analysis and make a 
direct comparison between the metastasis and matched primary ESCC. This study 
expands the registry of somatically-disrupted driver genes and reveals the critical genetic 
events underlying ESCC metastasis.  
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Methods and materials 
Study subjects 
Tumor samples and histologically non-neoplastic mucosae at surgical resection margins 
were obtained from 46 ESCC patients from Queen Mary Hospital. Institutional Review 
Board (IRB) approval was obtained and all the study subjects signed the consent form. 
Supplementary Table S1 details a description of the clinical characteristics of the cases. 
Fresh tumor samples from untreated patients were obtained at the time of surgery. Tumor 
cell contents from hematoxylin and eosin-stained frozen sections were estimated by a 
pathologist (AKY Lam). Only samples with a high percentage of tumor cells were 
selected for this study (Supplementary Table S2). Over 75% of the samples contained at 
least 60% tumor.  A total of 57 tumors from 46 ESCC cases were sequenced, including 
42 primary carcinomas and 15 LNs with metastatic carcinoma. For 11 of 46 ESCC cases, 
paired primary and matched LNs with metastatic carcinomas were available. 
 
Whole-exome sequencing  
Genomic DNAs were extracted from tumors and non-neoplastic mucosae at proximal 
surgical resection margins using the AllPrep DNA/RNA Mini kit (Qiagen). The extracted 
DNA was analyzed on 0.7% agarose gels and the quality and quantity were examined by 
Nanodrop 1000 (Thermo Scientific), Qubit (Life Technologies) and a bioanalyzer 
(Agilent), respectively. The library preparation, capture, and sequencing were performed 
by the Centre for Genomic Sciences at the University of Hong Kong. In brief, 250 ng 
genomic DNA were fragmented by an ultrasonicator (Covaris). These fragments were 
amplified using NEBNext UltraTM DNA library Prep Kit (NEB) and then hybridized to 
the Illumina TruSeq capture kit for enrichment. Paired end, 100 bp read-length 
sequencing was performed using the HiSeq 1500 sequencer (Illumina). 
 
WES data analysis:  detection of SNVs and small indels 
Clean sequencing reads were aligned to the human genome (hg19) with BWA12. Picards 
were applied to sort reads and mark duplicates. The paired or triple samples from the 
same cases were merged together. Subsequently, GATK13 was applied for local 
realignment around indels with base quality recalibration according to GATK Best 
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Practices recommendations14, 15.  After base quality recalibration, the merged reads were 
split for individual samples. The germline variants were identified by GATK and then 
examined for the number of singletons and to determine correct matching of samples 
from the same cases. SNVs were detected by Mutect16 and Varscan217. Small indels were 
detected by Varscan2. In Mutect, we removed the SNVs with less than 5 reads supporting 
a mutant allele in tumor samples. In Varscan2, we only considered the high-confidence 
SNVs and indels with variant allele frequency in the tumors >10%. SNVs with minor 
allele frequency (MAF) >1% in 1000 genomes and ESP6500 databases were further 
removed from the analysis. Recurrent somatic mutations and low-quality mutations 
(mutant allele frequency <10%) were manually checked in IGV alignment to further 
remove false positives based on mapping quality, base Phred quality score, and quality of 
adjacent regions. Loss-of-function (LOF) mutations were defined as stopgain, splicing, 
and frameshift indels.  
 
Detection of SCNVs 
We performed ADTEx18 to detect the somatic copy number variations (SCNVs). ADTEx 
is tailored for WES data, to infer SCNVs in ESCC genomes on the basis of normalized 
ratio of WES data from tumor and matched non-neoplastic mucosae.  
 
RNASeq and data analysis 
Four tumor pairs were subjected to RNASeq. Total RNAs were extracted by the AllPrep 
DNA/RNA Micro Kit (Qiagen). The ribosomal RNAs were depleted using the Ribo-Zero 
Magnetic Kit (Illumina). The Kapa Stranded RNA-seq Library Preparation kit was used 
for the library preparation and the libraries were subjected to high-throughput sequencing 
using the HiSeq 1500 sequencer with 100 bp paired-end reads. 
Clean reads were aligned to the human reference genome (hg19) using Tophat (version 
2.1.0 with Bowtie version 2.2.4), and the gene expression level (FPKM, fragments per 
kilobase per million fragments mapped) was calculated by Cufflinks19. For each gene, the 
median FPKM value is summarized across all the samples. 
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Statistical analysis 
Chi-square or Fisher's exact test was used to examine the difference of mutation 
frequency between groups. The difference of the quantitative data was tested by Mann-
Whitney U test.  In survival analysis, Kaplan-Meier analysis was used for survival curves 
with log-rank test for comparison between groups. A univariate Cox proportional hazards 
model was used to examine associations between overall survival and genetic alterations, 
as well as other clinical parameters.  In the multivariable survival analysis, this 
association between genetic alteration and overall survival was adjusted by clinical 
parameters including stage and age.  A p value <0.05 or false discovery rate (FDR) <0.20 
in the case of multiple test correction was considered statistically significant. The power 
estimation for the analysis, publicly available microarray and mutation data analyses, 
identification of driver mutations and enrichment test utilized are detailed in the 
supplementary methods. 
 
Sanger sequencing 
Sanger sequencing was used to verify the selected mutations identified from the WES 
data. PCR amplification was performed using FastStart Taq DNA polymerase with 20 ng 
of genomic DNA as template. The primers are listed in Supplementary Table S3.  
 
qPCR copy number analysis 
Copy number of CCND1, RNF168 and histone variants on 6p22.1 was assessed using 
frozen tumors and matched non-tumor tissues. Copy number was determined by 
quantitative PCR with DNA binding dye SYBR green and using the specific primer pairs 
(Supplementary Table S3). Gene METTL21A was used as a diploid control. We selected 
this control according to the WES data (Supplementary Figure S1). The copy number 
changes were estimated using the delta-delta Ct method6.  
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Results:  
Identification of somatic mutations in the primary tumors and metastatic LNs 
The median average on-target coverage was 76-fold, 79-fold and 71-fold for the non-
neoplastic  mucosae, primary tumors and LNs with metastatic ESCC, respectively 
(Supplementary Table S2). In 41 primary tumors, the median mutation rate is 3.6 
mutations per megabase (Mb) (range 1.5-11.2) in protein-coding regions and 2.8 non-
silent mutations per Mb (range 0.9-7.2) (Supplementary Table S4). This non-silent 
mutation rate is comparable to recently published mutation rates in ESCC from Chinese 
patients (2.4-2.9 mutations per Mb)6, 7, 9. In 15 LNs with metastatic ESCC, the median 
mutation rate is 3.6 per Mb (range 1.1-7.6) in protein-coding regions and 2.6 non-silent 
mutations per Mb (range 0.7-5.4) (Supplementary Table S5). There is no statistically 
significant difference in the mutation rate between primary cancers and metastatic LNs 
(Figure 1A, Supplementary Figure S2). Sanger sequencing on a subset of variants 
confirmed 96.4% (54 variants) somatic variants identified by WES (Supplementary 
Table S6).  
In the primary tumors, TP53 (90.5%), KMT2D (23.8%), CDKN2A (11.9%) and 
ZNF750 (9.5%) were significantly mutated with at least three non-silent mutations 
(MutSigCV p<0.001) (Figure 1B, Supplementary Table S7). In addition, multiple 
genes reported previously, including FAM135B (11.9%), NOTCH1 (9.5%), TET2 (9.5%), 
NFE2L2 (7.1%), RB1 (7.1%), FAT1 (7.1%) and NSD1 (7.1%) were mutated in at least 
5% of the cases.  In the metastatic LNs, four genes TP53 (67%), KMT2D (40%), ZNF750 
(13%). and IRF5 (13%) were mutated in at least two cases with MutSigCV p<0.001 
(Figure 1B, Supplementary Table S8). There is no pronounced difference in the 
mutation frequency of these genes between the primary and metastatic ESCCs (Figure 
1C). The gene mutation frequencies were also similar between the primary tumors with 
and without LN metastasis (Figure 1D).  
We further examined the mutation profiles of eleven cases with matched primary 
tumors and metastatic ESCC in LNs. The results showed that 50-80% of the protein-
altered mutations in the metastatic ESCC can be detected in the matched primary tumors 
(Supplementary Figure S3). The mutations of the putative driver genes were generally 
found in both primary and metastatic ESCCs (Supplementary Figure S4). SYNE1 was 
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recurrently mutated in metastatic ESCCs, while the reads supporting the mutations can be 
detected in the primary tumors at a much lower allele frequency and, thus, were rejected 
by Mutect and Varscan2 (Supplementary Figure S5). This result shows that the tumor 
cells in the metastatic ESCCs with SYNE1 mutations are likely to originate from a small 
subclone of the primary tumors.  
 
Mutational signatures in ESCC primary and metastatic LNs 
Similar to the previous findings for ESCC, two predominant signatures were identified in 
the primary tumors. Signature A is characterized as substitutions in CpG dinucleotides 
due to an increased rate of spontaneous 5-methyl-cytosine deamination. Signature B is 
characterized as substitutions involving C to G/T in TpCpX trinucleotides (Figure 2A 
and B), which was associated with the APOBEC-mediated mutations20. Interestingly, the 
APOBEC-mediated signature was weaker in the metastatic ESCC, when compared to 
primary tumors (p=0.025, Figure 2C and D, Supplementary Figure S6). We did not 
detect decreased tumor contents or coverage in metastatic ESCC LNs , when compared to 
primary tumors (Supplementary Figure S7).  Thus,  the weaker APOBEC-mediated 
signature in the metastatic ESCCs was not caused by differences in tumor contents and 
sequencing depth.  
 
TP53 mutations in ESCC primary and metastatic LNs 
TP53 was the most significantly mutated gene in the primary (90.5%) and metastatic 
ESCC (66.7%). Recurrent missense mutations p.R175H, p.Y220C, p.R248Q/W and 
p.R273C/H occurred in at least 5% of the primary tumors (Figure 3A).  The hot spots for 
TP53 missense mutation in the Hong Kong cohort were slightly shifted, when compared 
to the ESCC cases from high-risk regions (Taihang mountains and Chaoshan district), but 
were similar to the combined ESCC cases from high- and low- risk regions (Figure 3B, 
Supplementary Figure S8), suggesting that the ESCC of Hong Kong  cases are  a mixed 
cohort from different risk regions. Interestingly, the patients with TP53 missense 
mutations had much shorter survival times than patients with LOF mutations or without 
mutation (Figure 3C). The association between TP53 missense mutations and overall 
survival is independent from clinical parameters including stage and age (adjusted 
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HR=3.36, 95% CI: 1.51-7.49, p=0.003), while there is no statistical difference of survival 
between cases with LOF mutations or other mutations (Supplementary Table S9). In the 
metastatic ESCC in LNs, missense mutations p.R273H, p.R273C, p.V272M, p.I255F, 
p.V157A, p.F109C, truncating mutations p.R209* and p.S183*, frameshift indels 
p.T230fs and p.L93fs were identified (Figure 3A).  
 
ZNF750 LOF mutations in LN metastasis 
ZNF750 is a putative tumor suppressor in ESCC6, 8. In this study, it was mutated in both 
primary (9.5%) and metastatic ESCC (13%) (MutSigCV p<0.001). We identified three 
LOF and one missense mutation at ZNF750. We further examined 33 LOF ZNF750 
mutations identified from a total of 630 primary tumors in current and previous studies6-
10, accounting for 6.5% of the cases (Figure 4A). The result confirmed that these 
mutations occurred at a higher frequency in primary ESCCs with LN metastasis (10% vs. 
2.25%, p=0.0004, Figure 4B). In our samples, the ZNF750 LOF mutations including 
p.Y302* and p.F213fs were found in two metastatic ESCCs and matched primary tumors.  
ZNF750 deletion was observed in these two ESCCs carrying ZNF750 LOF mutations 
(Figure 4C), suggesting this gene was subjected to biallelic inactivation via mutation and 
deletion. At the mRNA level, downregulation of ZNF750 was found in over 80% of the 
cases (Supplementary Figure S9). Gene set enrichment analysis (GSEA) using the 
publicly available microarray data (GSE23400, n=53) indicates that ZNF750 expression 
correlated with the gene sets upregulated after knockdown of the polycomb repressive 
complex (PRC) 1 protein BMI1 and PRC2 protein SUZ2 (Figure 4D). This result implies 
its role in inhibition of cancer cell stemness. In addition, the ESCC survival analysis in 
from the TCGA study showed that the cases with genetic alterations including point 
mutations and copy number variations (CNVs) at ZNF750 had shorter disease relapse-
free survival, when compared to the  other cases (log-rank test p=0.0006, 
Supplementary Figure S10).  
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Identification of SCNAs in the primary and metastatic LNs 
High-frequency recurrent SCNAs (>45% of the cases affected) were identified including 
705 genes amplified and 84 genes deleted in 42 primary tumors (Supplementary Table 
S10) and 1106 genes amplified and 208 genes deleted in 15 metastatic ESCC in LNs 
(Supplementary Table S11). The deletions frequently occurred in 3p21, 6p22 (histone 
variants cluster 1), 9p21 (CDKN2A/CDKN2B), and 15q13-15, and amplifications were 
often identified in 3q12-13, 3q21-29 (PIK3CA/TERC/SOX2/TP63), 5p14-15 (TERT), 
8q21-24 (MYC), 11q13 (CCND1/FGFs/SHANK2) and 18p11 in both primary and 
metastatic ESCCs (Figure 1C and Figure 5). The qPCR copy number analysis was used 
to evaluate the accuracy of the SCNAs in CCND1 and histone variants from 6p22, and 
we confirmed these SCNAs in 83.3% of the samples (Supplementary Table S12).   
 
Nucleosome core deletion in late-stage primary tumors and metastatic LNs 
We further investigated the genes frequently deleted in metastatic ESCC in LNs. Out of 
208 genes deleted in at least 7 out of 15 cases, genes encoding nucleosomal histones were 
significantly enriched (adjusted p=7.0×10-9), but this enrichment was not observed in 84 
genes deleted in the primary tumors. These genes include a number of histones mainly 
from histone cluster 1 on 6p22 and H2A histone variant (H2AFX) on 11q23.3. We 
detected the 6p22.1-22.2 deletion in 38.1% of the primary tumors and 53.3% of ESCC in  
LNs (Figure 1C). A significant increase of deletion frequency was observed in the late-
stage primary, as well as metastatic ESCCss when compared to the early-stage primary 
ESCCs (Fisher's exact test p=0.007 and p=0.012, respectively) (Figure 6A, B and C). 
The cases harboring the 6p22 deletion or 11q23 deletion at H2AFX had much shorter 
overall survival than those without deletion in these two regions (Figure 6D), but this 
association is not independent from stage (Supplementary Table S9).  
 
Copy number gain in telomerase subunit genes in primary tumors and metastatic LNs 
Telomerase is an enzyme complex that adds telomeric repeats to the ends of 
chromosomes. The core components of telomerase include telomerase reverse 
transcriptase (TERT) and the telomerase RNA component (TERC)21. TERT is located at 
chromosome 15p13.33 and amplification of TERT region has been reported in ESCC11. 
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TERC maps to chromosome 3q26.  In the Hong Kong cohort, copy number gain at TERT 
and TERC was observed in 66.7% and 59.5% of the  primary tumors, respectively. 
Noticeably, the frequency of TERT copy number gain was reduced to 20% of the 
metastatic ESCC in LNs (p=0.028, FDR=0.18).  On the other hand, TERC copy number 
gain was  frequently observed in 66.7% of the metastatic cases   (Supplementary Table 
S10).  
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Discussion 
In this study, we investigated the genomic changes in the primary tumors and LNs with 
metastatic cancers in Hong Kong patients with ESCC. The mutation rates in the 
metastatic cancers were similar to those in the primary tumors. Generally, the mutations 
of the putative driver genes in the metastatic ESCC can be detected in the matched 
primary tumors. This could partially explain why ESCC is biologically so aggressive. 
The APOBEC-mediated signature was weaker in the metastatic cancers, although it is 
predominantly found in the primary tumors as reported in previous studies6, 8, as well as 
by us. The role of APOBEC-mediated signature in cancer metastasis has not been well-
studied.  It is reported that the APOBEC-attributable mutations may be early as well as 
late events during tumor evolution depending on the cancer type22. Several APOBEC 
members, including APOBEC3A, APOBEC3B and APOBEC1, may contribute to this 
mutation signature20. In colon cancer, APOBEC3G, a member of a cluster of proteins of 
which APOBEC1 is a prototype, was highly expressed in hepatic metastasis. It enhanced 
colon cancer cell migration and invasion.  Thus, APOBEC1promoted the  liver metastasis 
in colon cancer23. In ESCC, dramatic increase of APOBEC3B expression was observed8, 
while both APOBEC3A and APOBEC3G expression showed no difference between the 
tumor and non-neoplastic tissues (Supplementary Figure S11). Our data suggest that 
APOBEC3B may play a minor role for pathogenesis of metastasis in ESCC. 
TP53 is frequently mutated in the primary and metastatic ESCCs.  In ESCC, the 
hot spots for TP53 missense mutations are within the DNA binding domain. Previously, 
Lam et al. characterized TP53 mutations in patients with primary ESCC from Hong Kong 
by Sanger sequencing24. Similar to their findings, the mutations at codons p.R248 and 
p.R273 were common in our cohort. In addition, we found frequent mutations at codons 
p.R175 and p.Y220 in 7% of the cases.  Lam et al. reported that TP53 mutations appeared 
to have a role in predicting clinical outcome of patients with ESCC, although their result 
did not reach statistical significance24. In this study, we now further categorized TP53 
mutations as missense or LOF and demonstrated a significant association between TP53 
missense mutations and shorter overall survival of patients with ESCC. The association 
between the TP53 missense mutations and shorter overall survival indicate the important 
functional impact of these missense mutations in ESCC disease progression. Validation 
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of this association in a larger cohort of patients with ESCC in Hong Kong is warranted. 
Two missense mutations identified in the primary tumors were also found in the 
metastatic ESCC at codon p.R273 (p.R273C and p.R273H). Previous studies showed that 
the p.R273H and p.R273C mutants enhanced cell proliferation, invasion and drug 
resistance in lung and breast cancer cell lines in vitro25, and knock-in of p.R273H 
increased incidence of highly metastatic carcinomas for ovarian cancer in vivo26. The 
functional roles of these two mutations in ESCC remain unclear. Our data and previous 
studies imply that these two mutations are likely to be GOF mutations and contribute to 
metastasis in ESCC.  
IRF5 is a transcription factor and plays an important role to regulate B-cell 
differentiation27 and to modify the tumor immune microenvironment by regulating 
lymphocyte infiltration28. Mutation of IRF5 has not been emphasized in ESCC previously 
as its frequency is rather low in the primary tumors (<5%). We found this gene is 
recurrently mutated in metastatic ESCCs and is predicted to be one of the driver genes in 
metastasis. In breast cancer, reduced expression of IRF5 is reported in the metastatic 
cancer in LNs from invasive ductal carcinoma and IRF5 inhibits invasion and metastasis 
in vitro29.  IRF5 expression in tumor cells induces the expression of a number of 
cytokines and chemokines, including CXCL13 that plays an important role to recruit the 
tumor infiltration lymphocytes to the tumor site30. Use of a modified CXCL13 targeting 
both the regulator and effector of the immune system to control tumor cell escape can 
abrogate lung metastasis in the aggressive breast cancer model31. In ESCC, according to 
the microarray data (GSE23400), downregulation of IRF5 at the mRNA level was also 
observed (p=0.0015). Previous studies and our data suggest that IRF5 may also have a 
role in regulating a network of genes important for immune responses to ESCC cells and 
IRF5 mutations are likely to abrogate this function to promote cancer invasion and 
metastasis in ESCC. 
ZNF750 LOF mutations were discovered in the metastatic LN with tumors. An 
important association between ZNF750 mutations and LN metastasis was observed by 
combining the results of ESCC from previous studies. The genetic alterations at ZNF750 
were associated with shorter disease relapse-free survival of patients with esophageal 
cancer in the TCGA study. ZNF750 plays an essential regulatory role in controlling 
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epithelial homeostasis by inhibiting progenitor genes, while inducing differentiation32, 33. 
In squamous cell carcinomas, ZNF750 mutated  lesions were exclusively observed; it 
drives differentiation and regulates cell growth and migration34. In ESCC, evidence 
shows that ZNF750 knockdown strongly promotes cell proliferation, migration and 
invasion6. Gene set enrichment analysis further revealed that ZNF750 was associated 
with suppression of PRC1 protein BMI1 and PRC2 protein SUZ12. Expression of BMI1 
and SUZ12 was significantly elevated in ESCC (Supplementary Figure S12). BMI1, as 
an epigenetic regulator, maintains the self-renewal and proliferative capacity of the 
cells35. Previous study showed that BMI1 promotes metastasis and chemoresistance in 
melanoma36. In  tongue SCC, BMI1 mediates the podocalyxin (PODXL)-enhanced 
cisplatin chemoresistance37. Taken the data together, loss of wild-type ZNF750 may 
promote persistence of cancer-initiating cells, increased stemness, drug resistance and 
cell migration.  Therefore, we hypothesize that ZNF750 is a metastasis suppressor in 
ESCC.  Mutations of ZNF750, especially the LOF mutations, abrogate inhibition of 
metastasis.  
Epigenetic regulators KMT2D, KAT2A and TET2 were mutated in 60% of the 
metastatic ESCC, suggesting an important role of these histone modifiers for metastasis 
in ESCC. Recently, Sawada et al. reported that increased invasive activity of ESCC was 
observed after knockdown of TET2, which encodes a methylcytosine dioxygenase 
catalyzing the conversion of methylcytosine to 5-hydrxymethylcytosine10. KMT2D 
encodes a histone methyltransferase that methylates the lysine-4 position of histone H3. 
Mutation of KMT2D was frequently reported in the primary  ESCC tumors and most of 
the mutations are inactivating mutations6-10. We identified multiple mutations of KMT2D 
in the metastatic cancer in LNs of ESCC patients. Moreover, over 50% of the metastatic 
ESCC in LNs had 6p22 or 11q23 deletion and the cases with these deletions were 
associated with advanced cancer stage. Deletion of histone cluster 1 on 6p22.1 is not 
frequently reported in cancers, except in acute lymphoblastic leukemia in Downs’ 
syndrome, in which about 22% of the cases carry the deletion in this region38. Frequent 
deletion of 11q23 has been reported in several cancers including hematological 
malignancies and solid tumors39-41. Variant histone H2AFX on 11q23, also known as 
H2AX, plays essential roles in DNA double-strand break repair and genomic stability, and 
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thus, is well-accepted as a "histone guardian"42. In colon cancer cells, loss of H2AFX 
induces mesenchymal-like characteristics43. These studies suggest a role of H2AFX in 
cancer initiation, progression and metastasis. Our results suggest that genetic lesions of 
chromatin regulators and histone variants may function collectively leading to chromatin 
disorganization and abnormal DNA packaging, which may promote metastasis in ESCC. 
Telomeres are composed of the repetitive (TTAGGG)n repeats bound by 
shelterins, which protect them from being recognized as DNA double-strand breaks. The 
maintenance of telomere length is crucial for tumor cell survival. One of the mechanisms 
for maintenance of telomere length is through the reactivation of telomerase. Our WES 
data analysis in primary ESCC reinforces this idea by demonstration of frequent 
amplification of TERT at 5p15.33 (66.7%) in primary ESCC, as well as seen in a previous 
study11, regardless of early or late stage primary tumors. Interestingly, TERT 
amplification at 5p15.33 was detected with a reduced frequency (20%) in the metastatic 
ESCC. Our data suggest that TERT amplification at 5p15.33 may be one of the major 
mechanisms operating in primary ESCC for TERT reactivation for maintenance of 
telomere length, while TERT amplifications are negatively selected in metastatic ESCC. 
However, we cannot completely rule out that TERT promoter mutations or structural 
rearrangements exist in the metastatic ESCC due to limitations of WES analysis.  Further 
studies are needed to better answer the role of telomere biology in ESCC metastasis. 
In summary, this study characterized the genomic landscape of the primary 
tumors and metastatic cancers in patients with ESCC in Hong Kong. Our study highlights 
the role of TP53 GOF mutations, genetic lesions in differentiation regulators ZNF750 and 
IRF5, epigenetic regulators and histone variants in metastatic ESCC, which are expected 
to aid in identifying the therapeutic and actionable targets and development of precision 
medicine for this deadly cancer.  
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Figure legends 
Figure 1: Genomic alterations in Hong Kong ESCC. A) Mutation rate and number of 
protein-altered mutations in primary and metastatic tumors. B) Mutation landscape of 
significantly mutated genes and relevant pathways in primary and metastatic tumors.  * 
indicates the genes significantly mutated in the primary tumors (MutSigCV p<0.001) and 
the genes significantly mutated in the metastatic LNs are highlighted in orange 
(MutSigCV p<0.001). C) Frequency of SNVs and SCNVs in the primary and metastatic 
tumors. D) Frequency of SNVs and SCNVs in the stage I-II (early) and III-IV (late) 
primary tumors. **p<0.01 in Fisher's exact test. 
 
Figure 2: Mutational signature in Hong Kong ESCC. A and B) Ninety-six substitution 
classifications from WES data derived from primary and metastatic tumors, respectively. 
Substitution types are displayed in different colors on the horizontal axis. The vertical 
axis indicates the proportion of each substitution pattern. Trinucleotide contexts of 
mutations occurring at cytosine nucleotides in primary and metastatic tumors are on the 
top right corner. Font size of the bases at 5' and 3' positions are proportional to the 
frequencies. C) The contribution of mutation signatures to the total variant number in 
each tumors. D) The contribution of mutation signatures in the stage I-II (early), III-IV 
(late) primary tumors and metastatic LNs (MET).  
 
Figure 3: TP53 mutations in ESCC. A) TP53 mutations in primary tumors and 
metastatic cancer in LNs from patients with ESCC in Hong Kong. The amino acids with 
mutation frequencies >5% in primary tumors are highlighted. B) Distribution of TP53 
missense mutations in Hong Kong, high-risk and low-risk regions of mainland China, and 
Japan, respectively (top), and mixed  cohorts of patients with ESCC from mainland China 
and Japan (bottom). X-axis shows the position of amino acid in TP53. Y-axis shows the 
density of missense mutations. C) Kaplan-Meier analysis of survival curves for the cases 
with missense, LOF or no mutations.  
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Figure 4: ZNF750 in ESCC.  A) ZNF750 mutations in ESCC from current and previous 
studies (n=630). Asterisk indicates the truncating mutations. B) ZNF750 mutation in 
ESCC with and without LN metastasis in the current and previous study cohort. 
****p<0.0001; ***p<0.001; +p<0.1. C) ZNF750 copy number in ESCC with LOF 
mutation. D) Gene Set Enrichment Analysis (GSEA) in microarray data (GSE23400) 
between the ESCC cases with high and low ZNF750 expression (median as cut-off).   
 
Figure 5: Copy number variations in ESCC primary tumors and metastatic LN, 
respectively. Red color indicates copy number loss (CN loss), blue color indicates copy 
number gain (CN gain). Green color indicates no copy number changes.  
 
Figure 6: Deletion of histone variants on 6p22 in ESCC. A) Deletion frequency in 
ESCC. p value was estimated by Fisher's exact test. B) ESCCs with and without 6p22 
deletion. Red color indicates copy number loss. Green color indicates no copy number 
changes. C) Genes within the deleted region on 6p22. D) Survival curves of the patients 
with and without deletion on 6p22 (histone cluster 1) or on 11q23 (H2AFX). p value was 
estimated by log-rank test.  
